LEMS Treatment Mechanisms: Immunosuppression, Plasma Exchange, and Potassium Channel Blockade

In "LEMS Treatment Mechanisms: Immunosuppression, Plasma Exchange, and Potassium Channel Blockade," our experts turn to how each LEMS treatment actually works at the cellular level.

Dr. Iams sets up the treatment discussion by naming the historical options: steroids, IVIG, plasmapheresis, and treatment of the underlying malignancy, then asks Dr. Patel to add amifampridine into the picture. Dr. Patel explains that the first several options share a common goal, keeping autoantibodies from attacking voltage-gated calcium channels, but each achieves it differently and they can be combined synergistically. Immunosuppressants target B cells and plasma cells to reduce antibody production, while IVIG works by blocking the antibody from reaching its target. Plasma exchange physically filters existing antibodies out of the blood. Treating the underlying cancer functions as source control, since removing the antigenic stimulus is, as Dr. Patel puts it, similar to draining an abscess that is driving a bloodstream infection. Amifampridine, he says, works differently and offers something closer to instant gratification because of its faster mechanism. Rather than targeting the antibody directly, it blocks potassium channels in nerve cells, which keeps calcium channels open longer. Since the underlying problem was insufficient calcium entering the presynaptic terminal, this effect allows more calcium into the synapse, which in turn permits more acetylcholine release at the neuromuscular junction. That additional acetylcholine restores more normal firing and produces measurable strength gains. Dr. Patel contrasts this with the other therapies, which require time for antibody levels to fall before downstream improvement in neuromuscular function becomes apparent. Dr. Iams calls the explanation a clear, well-distilled way to understand why amifampridine's onset differs so notably from the immune-targeted approaches discussed earlier in the conversation.

In "LEMS Therapy Access: Candidate Selection and NCCN Guideline Support," the panel will get specific about who is a good candidate for this therapy and how access and ordering actually work.